Thymosin Alpha-1 vs Semaglutide
Side-by-side comparison of key properties, dosing, and research.
Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1GLP-1 / Weight Loss Agonists
Semaglutide- Summary
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- Half-Life
- 2–3 hours
- ~7 days
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.8–1.6 mg
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Twice weekly
- Once weekly, subcutaneous
- Key Benefits
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Side Effects
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Stacks With
- —
- —